345 related articles for article (PubMed ID: 10477554)
41. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine.
Reynolds SR; Oratz R; Shapiro RL; Hao P; Yun Z; Fotino M; Vukmanović S; Bystryn JC
Int J Cancer; 1997 Sep; 72(6):972-6. PubMed ID: 9378560
[TBL] [Abstract][Full Text] [Related]
42. Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor.
Voelter V; Rufer N; Reynard S; Greub G; Brookes R; Guillaume P; Grosjean F; Fagerberg T; Michelin O; Rowland-Jones S; Pinilla C; Leyvraz S; Romero P; Appay V
Int Immunol; 2008 Aug; 20(8):1087-96. PubMed ID: 18573812
[TBL] [Abstract][Full Text] [Related]
43. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
[TBL] [Abstract][Full Text] [Related]
44. Mature dendritic cells prime functionally superior melan-A-specific CD8+ lymphocytes as compared with nonprofessional APC.
Salio M; Shepherd D; Dunbar PR; Palmowski M; Murphy K; Wu L; Cerundolo V
J Immunol; 2001 Aug; 167(3):1188-97. PubMed ID: 11466333
[TBL] [Abstract][Full Text] [Related]
45. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.
Dhodapkar MV; Young JW; Chapman PB; Cox WI; Fonteneau JF; Amigorena S; Houghton AN; Steinman RM; Bhardwaj N
Clin Cancer Res; 2000 Dec; 6(12):4831-8. PubMed ID: 11156242
[TBL] [Abstract][Full Text] [Related]
46. Thymic selection generates a large T cell pool recognizing a self-peptide in humans.
Zippelius A; Pittet MJ; Batard P; Rufer N; de Smedt M; Guillaume P; Ellefsen K; Valmori D; Liénard D; Plum J; MacDonald HR; Speiser DE; Cerottini JC; Romero P
J Exp Med; 2002 Feb; 195(4):485-94. PubMed ID: 11854361
[TBL] [Abstract][Full Text] [Related]
47. Lack of functionally active Melan-A(26-35)-specific T cells in the blood of HLA-A2+ vitiligo patients.
Adams S; Lowes MA; O'Neill DW; Schachterle S; Romero P; Bhardwaj N
J Invest Dermatol; 2008 Aug; 128(8):1977-80. PubMed ID: 18337837
[TBL] [Abstract][Full Text] [Related]
48. Diverse expansion potential and heterogeneous avidity in tumor-associated antigen-specific T lymphocytes from primary melanoma patients.
Palermo B; Campanelli R; Mantovani S; Lantelme E; Manganoni AM; Carella G; Da Prada G; della Cuna GR; Romagne F; Gauthier L; Necker A; Giachino C
Eur J Immunol; 2001 Feb; 31(2):412-20. PubMed ID: 11180105
[TBL] [Abstract][Full Text] [Related]
49. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients.
Meidenbauer N; Marienhagen J; Laumer M; Vogl S; Heymann J; Andreesen R; Mackensen A
J Immunol; 2003 Feb; 170(4):2161-9. PubMed ID: 12574389
[TBL] [Abstract][Full Text] [Related]
50. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
[TBL] [Abstract][Full Text] [Related]
51. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.
Maeurer MJ; Gollin SM; Martin D; Swaney W; Bryant J; Castelli C; Robbins P; Parmiani G; Storkus WJ; Lotze MT
J Clin Invest; 1996 Oct; 98(7):1633-41. PubMed ID: 8833913
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.
Asai T; Storkus WJ; Whiteside TL
Clin Diagn Lab Immunol; 2000 Mar; 7(2):145-54. PubMed ID: 10702485
[TBL] [Abstract][Full Text] [Related]
53. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
[TBL] [Abstract][Full Text] [Related]
54. Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1.
Ramirez-Montagut T; Andrews DM; Ihara A; Pervaiz S; Pandolfi F; Van Den Elsen PJ; Waitkus R; Boyle LA; Hishii M; Kurnick JT
Clin Exp Immunol; 2000 Jan; 119(1):11-8. PubMed ID: 10606959
[TBL] [Abstract][Full Text] [Related]
55. Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.
Serana F; Sottini A; Caimi L; Palermo B; Natali PG; Nisticò P; Imberti L
J Transl Med; 2009 Mar; 7():21. PubMed ID: 19317896
[TBL] [Abstract][Full Text] [Related]
56. An antigen-targeted approach to adoptive transfer therapy of cancer.
Valmori D; Pittet MJ; Rimoldi D; Liénard D; Dunbar R; Cerundolo V; Lejeune F; Cerottini JC; Romero P
Cancer Res; 1999 May; 59(9):2167-73. PubMed ID: 10232604
[TBL] [Abstract][Full Text] [Related]
57. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination.
Speiser DE; Baumgaertner P; Barbey C; Rubio-Godoy V; Moulin A; Corthesy P; Devevre E; Dietrich PY; Rimoldi D; Liénard D; Cerottini JC; Romero P; Rufer N
J Immunol; 2006 Jul; 177(2):1338-48. PubMed ID: 16818795
[TBL] [Abstract][Full Text] [Related]
58. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
Dangoor A; Lorigan P; Keilholz U; Schadendorf D; Harris A; Ottensmeier C; Smyth J; Hoffmann K; Anderson R; Cripps M; Schneider J; Hawkins R
Cancer Immunol Immunother; 2010 Jun; 59(6):863-73. PubMed ID: 20043222
[TBL] [Abstract][Full Text] [Related]
59. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines.
Anichini A; Scarito A; Molla A; Parmiani G; Mortarini R
J Immunol; 2003 Aug; 171(4):2134-41. PubMed ID: 12902520
[TBL] [Abstract][Full Text] [Related]
60. Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring.
Speiser DE; Pittet MJ; Guillaume P; Lubenow N; Hoffman E; Cerottini JC; Romero P
J Immunother; 2004; 27(4):298-308. PubMed ID: 15235391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
